LNG-POP Levonorgestrel 0.135 mg Tablet clinical trials

A mono-centre, non-comparative clinical trial on the inhibition of ovulation with LNG POP (Levonorgestrel tablet, 0.135 mg) during three 28-day cycles with continuous treatment and intentional intake errors

This study looks at a daily contraception pill (containing levonorgestrel) to see how well it stops women from ovulating. Researchers want to know how effective it is, even if a dose is missed on purpose, to understand its real-world use.